news
Novel nanoparticle therapy shows promise in glioblastoma
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
List view / Grid view
Oncology
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
news
Age may be a primary determinant of melanoma treatment resistance
Scientists have shown that age may cause genetically identical melanoma skin cancer cells to respond differently to treatment, making age a primary factor in treatment response.
news
Researchers discover novel cancer immunosuppression mechanism
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
news
Scientists identify new way to target leukaemia cells
Researchers have found they can make leukaemia cells vulnerable by dislodging leukaemia stem cells from a tumour-promoting niche.
news
Organs-on-a-chip model for breast cancer drug cardiac toxicity testing
The newly developed chip includes heart and breast cancer tissues and could be used to predict the cardiac toxicity of chemotherapeutic drugs.
news
Novel vaccine protects mice from lung, bowel and pancreatic cancer
By targeting the mutated KRAS gene, researchers have developed an experimental vaccine that protected mice against a range of cancers.
news
Long non-coding RNAs could be future targets for cancer drugs
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
news
CRISPR used to eliminate cancers caused by fusion genes
Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
news
Lead drug candidate identified as potential neuroblastoma treatment
Using hit-to-lead processes, researchers have discovered that KSP inhibitors prevent tumour growth and prolong survival in mice with neuroblastoma.
![Ovarian cancer cells forming a cancer spheroid as they grow within the peptide-protein co-assembling material [Credit: Alvaro Mata].](https://www.drugtargetreview.com/wp-content/uploads/ovarian-cancer-spheroid-3D-model-750x500.jpg)
![Ovarian cancer cells forming a cancer spheroid as they grow within the peptide-protein co-assembling material [Credit: Alvaro Mata].](https://www.drugtargetreview.com/wp-content/uploads/ovarian-cancer-spheroid-3D-model-e1601896830935.jpg)
news
Novel tumour spheroids could improve ovarian cancer treatments
Researchers have developed a new self-assembling three-dimensional (3D) ovarian cancer tumour model to recreate the in vitro disease more accurately.
![Glioblastoma Multiforme (GBM) cells in culture [Credit: Dr Jin-Min Nam].](https://www.drugtargetreview.com/wp-content/uploads/glioblastoma-cells-750x500.jpg)
![Glioblastoma Multiforme (GBM) cells in culture [Credit: Dr Jin-Min Nam].](https://www.drugtargetreview.com/wp-content/uploads/glioblastoma-cells-e1601552379990.jpg)
news
Identifying radioresistance drivers in glioblastoma multiforme
According to researchers, Rab27b and epiregulin contribute to the development of radioresistance and could be targeted to improve glioblastoma patient survival.
news
Circular RNA revealed as drug target for lung squamous cell cancer
After finding that the circular RNA called CDR1as plays a role in driving metastasis, researchers have identified it as a potential target for lung squamous cancer.
news
Pathway to combat chronic myelogenous leukaemia identified in study
Researchers have discovered that disrupting the Gdpd3 gene significantly reduced chronic myelogenous leukaemia relapse in mice.
article
Developing IL-15 superagonists for cancer therapy
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
article
The next generation of cancer immunotherapies: re-exploring the IL-2 pathway
In this article, Dr Bruce Dezube explains why new cancer immunotherapy drugs that utilise the IL-2 pathway with lower side effects could offer more benefits compared to high-dose IL-2 treatment.
